NCT02797132View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

LUM/IVA

Trial Locations (20)

Unknown

Palo Alto

Aurora

Chicago

Indianapolis

Boston

Minneapolis

Kansas City

Buffalo

Chapel Hill

Cincinnati

Cleveland

Columbus

Philadelphia

Charleston

Houston

Norfolk

Seattle

Vancouver

Toronto

Montreal

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02797132 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | Biotech Hunter | Biotech Hunter